XML 39 R26.htm IDEA: XBRL DOCUMENT v3.25.1
Stockholders' Equity (Tables)
3 Months Ended
Mar. 31, 2025
Equity [Abstract]  
Schedule of Reconciliation of Common Stock Outstanding
The following table provides a reconciliation of the beginning and ending shares of common stock outstanding for the three months ended March 31, 2025, and the twelve months ended December 31, 2024:
THREE MONTHS ENDED MARCH 31, 2025TWELVE MONTHS ENDED DECEMBER 31, 2024
Balance, beginning of period350,532,006 380,964,433 
Issuance of common stock— 8,623 
Conversion of OP units to common stock— 194,767 
Shares Repurchased— (30,794,250)
Non-vested share-based awards, net of withheld shares and forfeitures464,163 158,433 
Balance, end of period350,996,169 350,532,006 
Schedule of Earnings (Loss) per Share
The following table sets forth the computation of basic and diluted earnings per common share for the three months ended March 31, 2025 and 2024.
THREE MONTHS ENDED MARCH 31,
Dollars in thousands, except per share data20252024
Weighted average common shares outstanding
Weighted average common shares outstanding350,758,618 381,335,208 
Non-vested shares(1,219,619)(1,880,401)
Weighted average common shares outstanding - basic349,538,999 379,454,807 
Weighted average common shares outstanding - basic349,538,999 379,454,807 
Dilutive effect of OP Units— — 
Weighted average common shares outstanding - diluted349,538,999 379,454,807 
Net loss$(45,389)$(315,220)
Income allocated to participating securities(612)(693)
Loss attributable to non-controlling interest516 4,384 
Adjustment to loss attributable to non-controlling interest for legally outstanding restricted units(17)(1,341)
Net loss applicable to common stockholders - basic and diluted$(45,502)$(312,870)
Basic earnings per common share - net loss$(0.13)$(0.82)
Diluted earnings per common share - net loss$(0.13)$(0.82)
Schedule of Stock Options, Valuation Assumptions The Company utilized a Monte Carlo simulation to calculate the weighted average grant date fair value of $19.47 for the February 2025 grant using the following assumptions:
Volatility28.0 %
Dividend assumptionAccrued
Expected term 3 years
Risk-free rate4.35 %
Stock price (per share)$16.17
The Company utilized a Monte Carlo simulation to calculate the weighted average grant date fair value of $9.88 for the February 2025 grant using the following assumptions:
Volatility28.0 %
Dividend assumptionAccrued
Expected term 3 years
Risk-free rate4.35 %
Stock price (per share)$16.17
Schedule of the Activity Under the Incentive Plan and RSU Activity
The following table represents the summary of non-vested share-based awards under the Incentive Plan for the three months ended March 31, 2025, and 2024:
THREE MONTHS ENDED MARCH 31,
 20252024
Share-based awards, beginning of period1,799,737 2,615,562 
Granted 1
919,937 1,475,811 
Vested(39,970)(28,414)
Change in awards based on performance assessment(59,762)— 
Forfeited— (19,805)
Share-based awards, end of period2,619,942 4,043,154 
1LTIP-C units are issued at the maximum number of units of the award and are reflected as such in this table until the performance conditions have been satisfied, and the exact number of awards are determinable.
Schedule of Unrecognized Compensation Cost, Nonvested Awards
The following table represents expected amortization of the Company's non-vested awards issued as of March 31, 2025:
Dollars in millionsFUTURE AMORTIZATION
of non-vested shares
2025$9.8 
202610.4 
20278.2 
20281.7 
2029 and thereafter0.6 
Total$30.7